The historical rank and industry rank for Encore Medical's Gross Margin % or its related term are showing as below:
EMI's Gross Margin % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 52.07 * Ranked among companies with meaningful Gross Margin % only.
Encore Medical had a gross margin of 47.88% for the quarter that ended in Dec. 2025 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Encore Medical was 0.00% per year.
Encore Medical (AMEX:EMI) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Encore Medical had a gross margin of 47.88% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Encore Medical Gross Margin % Related Terms
Encore Medical Gross Margin % Historical Data
* Premium members only.
The historical data trend for Encore Medical's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Encore Medical's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Encore Medical Gross Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Encore Medical's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Encore Medical's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Encore Medical (EMI) has a Gross Margin % of 47.88% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Encore Medical and its competitors.
Is Encore Medical's Gross Margin % too high?
Encore Medical's current Gross Margin % is 47.88%. The Medical Devices & Instruments industry median Gross Margin % is 52.07. Encore Medical's value of 47.88% is 8% below this industry median.
How does Encore Medical's Gross Margin % compare to ?
Encore Medical's Gross Margin % of 47.88% can be compared against companies in the Medical Devices & Instruments industry. The industry median Gross Margin % is 52.07. Encore Medical's value of 47.88% is 8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Medical Devices & Instruments company?
The median Gross Margin % among Medical Devices & Instruments companies is 52.07, based on 805 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Encore Medical's current Gross Margin % of 47.88% is 8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Encore Medical and its competitors. For the Medical Devices & Instruments industry, the median Gross Margin % is 52.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Encore Medical's current Gross Margin % is 47.88%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Encore Medical stock overvalued right now?
Encore Medical (EMI) has a current Gross Margin % of 47.88%. The current Gross Margin % is 47.88% and 8% below the Medical Devices & Instruments industry median of 52.07. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Encore Medical (EMI), the current Gross Margin % is 47.88% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Encore Medical Inc develops, manufactures, and markets septal occlusion devices for the repair of certain cardiac defects. Its products have been implanted in approximately 35,000 patients outside the United States. Its closure device is designed to correct a cardiac defect, generally diagnosed in adulthood, known as a patent foramen ovale (PFO). The company also currently market and sell septal occlusion devices for the transcatheter closure of atrial septal defects (ASD).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EMI has been successfully added to your